TREA

90812301 - ACCRETAMAB

Follow

Information

  • Trademark
  • 90812301
  • Serial Number
    90812301
  • Registration Number
    7102836
  • Filing Date
    July 06, 2021
    4 years ago
  • Registration Date
    July 11, 2023
    2 years ago
  • Transaction Date
    July 11, 2023
    2 years ago
  • Status Date
    July 11, 2023
    2 years ago
  • Published for Opposition Date
    April 25, 2023
    2 years ago
  • Location Date
    July 11, 2023
    2 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    MESSICK, TABITHA LEE
  • Attorney Docket Number
    TM21-706
    Attorney Name
    Kaushal Odedra
    Law Office Assigned Location Code
    L40
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
ACCRETAMAB
Case File Statements
  • GS0051: Host cells for medical or clinical use; cells for medical use, namely, cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; cells for medical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors being pharmaceutical products for treatment of blood pressure, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives for pharmaceutical purposes, antacids, hormones in the nature of pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis; pharmaceuticals, namely, corticosteroids for treatment of hypopituitarism, of congenital adrenal hyperplasia, of rheumatoid arthritis, of rheumatic fever, of crohn's disease, and of chronic active hepatitis; pharmaceuticals, namely, estrogen preparations and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents; pharmaceuticals, namely, cataplasms being medical plasters for the treatment of bruises, lumbago and stiff shoulder; pharmaceuticals, namely, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents in the nature of vitamins for treating vitamin deficiencies, anti-coagulants, enzyme preparations for medical purposes for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs delivery agents in the form of capsules, liquids, powders, patches for treating peptic ulcers, charred drugs delivery agents in the form of capsules, liquids, powders, patches for treating peptic ulcers, moxa in the nature of cone or stick made of ground mugwort leaves for treating peptic ulcers; pharmaceuticals, namely, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs; pharmaceuticals, namely, germination controllers and plant rearing agents in the nature of herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and agricultural use; pharmaceuticals, namely, antiseptics, pharmaceutical drugs in the nature of drug delivery agents in the form of coatings for tablets for the treatment of arteriosclerosis, oncostatic drugs in the nature of pharmaceutical products for the treatment for cancer, multienzyme digestants for pharmaceutical in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, drugs in the nature of pharmaceutical products for the prevention and treatment of parkinsonism, minor tranquilizers, and anti anxiety agents; pharmaceuticals, namely, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system; pharmaceuticals, namely, anti-bacterial preparations in the nature of antibacterial substances for medical purposes, monolithic preparations in the nature of substances for medical purposes, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations in the nature of radioactive substances and nutritive substances for microorganisms for medical purposes, pharmaceutical preparations for improving the metabolism and the peripheral circulation, blood plasma in the nature of plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media for medical use, and pharmaceutical preparations for the treatment of insomnia and other sleep related diseases; all the foregoing pharmaceuticals and vaccines comprising monoclonal antibodies
Case File Event Statements
  • 7/11/2023 - 2 years ago
    26 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 7/11/2023 - 2 years ago
    25 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 4/25/2023 - 2 years ago
    24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 4/25/2023 - 2 years ago
    23 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/5/2023 - 2 years ago
    22 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 3/17/2023 - 2 years ago
    21 - ELECTRONIC RECORD REVIEW COMPLETE Type: FIXD
  • 3/10/2023 - 2 years ago
    20 - ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Type: ERRR
  • 3/7/2023 - 2 years ago
    19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/14/2023 - 3 years ago
    18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/14/2023 - 3 years ago
    17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 2/14/2023 - 3 years ago
    16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 8/31/2022 - 3 years ago
    15 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 8/31/2022 - 3 years ago
    14 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 8/31/2022 - 3 years ago
    13 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 7/30/2022 - 3 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/29/2022 - 3 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/29/2022 - 3 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/16/2022 - 4 years ago
    9 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 2/16/2022 - 4 years ago
    8 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/16/2022 - 4 years ago
    7 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/9/2022 - 4 years ago
    6 - ASSIGNED TO EXAMINER Type: DOCK
  • 9/20/2021 - 4 years ago
    5 - PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Type: AMPX
  • 9/17/2021 - 4 years ago
    4 - ASSIGNED TO LIE Type: ALIE
  • 7/21/2021 - 4 years ago
    3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 9/14/2021 - 4 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 7/9/2021 - 4 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP